Transcript of the earnings conference call of Q4FY26
SYMPHONY · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Symphony Limited reported FY26 consolidated revenue of ₹1,131 crores, down 28% Y-o-Y, with PAT at negative ₹141 crores after taking ₹259 crores impairment related to Australia business. The company impaired the entire ₹348 crores equity investment in Australia (including ₹298 crores in FY26) and decided no further capital will be deployed there. USA business has been ring-fenced as a direct subsidiary with Symphony India acquiring Bonaire USA for ₹30 crores and related IPRs for ₹23 crores. Q4 consolidated revenue was ₹338 crores (down from ₹488 crores), with gross margin maintained at 46.4% but EBITDA margin declined to 15.5% from 21.2% due to operating leverage impact. The Beyond India Summer Products (BISP) portfolio contributed ₹558 crores (49% of revenue), diversifying from seasonal dependency. Subsidiaries IMPCO Mexico and GSK China remain profitable, with GSK China nearly debt-free (₹4 crores outstanding from peak ₹60 crores).
The Australia impairment cleans up the balance sheet and removes a multi-year drag on profitability. Management's focus on capital efficiency and debt reduction in subsidiaries positions the company for improved ROCE, though near-term earnings remain pressured by weak Indian summer demand and channel inventory overhang.